Iovance Biotherapeutics Inc (NAS:IOVA)
$ 9.32 -0.08 (-0.85%) Market Cap: 2.84 Bil Enterprise Value: 2.52 Bil PE Ratio: 0 PB Ratio: 3.67 GF Score: 39/100

Q4 2020 Iovance Biotherapeutics Inc Earnings Call Transcript

Feb 25, 2021 / 09:30PM GMT
Release Date Price: $36.51 (-7.38%)
Operator

Good afternoon, and welcome to the Iovance Fourth Quarter and Full Year 2020 Financial Results Conference Call. (Operator Instructions)

I would like to turn the call over to your speaker, Sara Pellegrino, Vice President, Investor and Public Relations at Iovance. Please go ahead.

Sara Pellegrino
Iovance Biotherapeutics, Inc. - VP of IR & Public Relations

Thank you, operator. Good afternoon, and thank you for joining us. Speaking on today's call, we have Maria Fardis, our President and Chief Executive Officer; Friedrich Finckenstein, our Chief Medical Officer; and Jean-Marc Bellemin, our Chief Financial Officer. We are also joined by Jim Ziegler, Senior Vice President, Commercial.

This afternoon, we issued a press release that can be found on our website at iovance.com, which includes the financial results for the 3 and 12 months ended on December 31, 2020, as well as corporate update.

Before we start, I would like to remind everyone that statements made during this conference call will include forward-looking statements

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot